All In Biotech

BLA 761174 · Glaxosmithkline

Jemperli

Dostarlimab-Gxly · Injection · Programmed Death Receptor-1 Blocking Antibody

NovelBreakthrough therapyAccelerated approvalPriority review

CDER novel approval, Apr 22, 2021: To treat endometrial cancer

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Apr 22, 2021

Approved uses

6

Original approval plus efficacy supplements

Registered trials

103

15 Phase 3, 31 recruiting

FAERS reports

2,493

2,141 serious, 296 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 19, 2026.

JEMPERLI is a programmed death receptor‑1 (PD‑1)–blocking antibody indicated: Endometrial Cancer • in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC). ( 1.1 ) • as a single agent for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced EC, as determined by an FDA‑authorized test, that has progressed on or following prior treatment with a platinum‑containing regimen in any setting and are not candidates for curative surgery or radiation. ( 1.1 , 2.1 ) Microsatellite Instability–High or Mismatch Repair Deficient Locally Advanced Rectal Cancer • as a single agent for the treatment of adult patients with Stage II/III, locally advanced rectal cancer (LARC) that is microsatellite instability‑high (MSI‑H) or dMMR, as determined by an FDA‑authorized test for solid tumors. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on sustained clinical complete response for 12 months. The long-term risk of relapse is unknown, with additional follow-up expected. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.2 ) Mismatch Repair Deficient Recurrent or Advanced Solid Tumors • as a single agent for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA‑authorized test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. ( 1.3 , 2.1 ) This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be...

Mechanism: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Dostarlimab-gxly is a humanized monoclonal antibody of the IgG4 isotype that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models,...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 19, 2026 Supplement 15 · Efficacy · priority review LabelLetterMedication Guide
  • Aug 1, 2024 Supplement 9 · Efficacy · priority review Label
  • Jul 31, 2023 Supplement 6 · Efficacy · priority review Breakthrough therapyLabelLetterReview
  • Feb 9, 2023 Supplement 4 · Efficacy LabelLetter
  • Feb 9, 2023 Supplement 3 · Efficacy LabelLetter
  • Apr 22, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelLetterReview
1 products under this application
  • JEMPERLI · DOSTARLIMAB-GXLY 500MG/10ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dostarlimab" as an intervention, any sponsor and status, largest first.

All 103 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • malignant neoplasm progression254
  • off label use145
  • fatigue133
  • rash114
  • anaemia98
  • arthralgia87
  • diarrhoea87
  • death84
  • neuropathy peripheral82
  • thrombocytopenia80
  • nausea70
  • hypothyroidism66

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20182
20199
202040
2021188
2022174
2023171
2024422
2025742
2026745

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Jemperli (Dostarlimab-Gxly)

2024 spending

$3.1M

Beneficiaries

48

232 claims

Per beneficiary

$65,089

$1,111.84 per unit

View as table
YearSpending
2020$0
2021$0
2022$360,508
2023$1,596,066
2024$3,124,278

Part B: Jemperli (Dostarlimab-Gxly) · HCPCS J9272

2024 spending

$142M

Beneficiaries

1,770

9,109 claims

Per beneficiary

$80,337

2024 ASP limit $234.67 per unit

View as table
YearSpending
2020$0
2021$0
2022$4,502,157
2023$35,992,091
2024$142,196,684

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 48 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.